S100A12 Recombinant Rabbit mAb (SDT-2776-47-2)

S100A12, a calcium-binding protein primarily expressed in granulocytes, has emerged as a promising biomarker for Alzheimer’s disease (AD), offering significant diagnostic value beyond traditional markers. Unlike amyloid-beta or tau proteins, which reflect core AD pathology but often require invasive cerebrospinal fluid (CSF) sampling or expensive PET imaging, S100A12 can be detected in peripheral blood, providing a less invasive and more accessible diagnostic tool.

Research indicates that S100A12 levels are significantly elevated in the blood and brain tissues of AD patients compared to healthy controls. This elevation correlates with neuroinflammation, a critical driver of AD progression. S100A12 activates the receptor for advanced glycation end products (RAGE), triggering inflammatory cascades that exacerbate neuronal damage and cognitive decline. Consequently, high S100A12 levels not only aid in distinguishing AD from other dementias but also potentially reflect disease severity and activity.

The diagnostic significance lies in its ability to detect early-stage inflammation before substantial neurodegeneration occurs. When combined with existing biomarkers, S100A12 improves diagnostic accuracy and sensitivity. Furthermore, monitoring S100A12 dynamics could help track therapeutic responses to anti-inflammatory treatments. While further large-scale clinical validation is needed, S100A12 represents a valuable, cost-effective addition to the AD diagnostic arsenal, facilitating earlier intervention and better management of this devastating neurodegenerative disorder through a simple blood test.